research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-23. Anything still debated is marked as such rather than presented as settled.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
=== Films depicting Cold War espionage === Tinker Tailor Soldier Spy is a 2011 Cold War spy thriller adaptation of the 1974 John le Carré novel of the same name. It is set in London in the early 1970s and follows the hunt for a Soviet double agent at the top of the British secret service. The Spy Who Came In from the Cold is a 1965 British Cold War spy film based on the 1963 John le Carré novel. The film depicts a British agent's mission as a faux defector to East Germany to sow damaging disinformation about a powerful East German intelligence officer. Firefox is a 1982 film based on a Craig Thomas novel of the same name. The plot details an American plot to steal a highly advanced Soviet fighter aircraft (MiG-31 Firefox) which is capable of Mach 6, is invisible to radar, and carries weapons controlled by thought. The Hunt for Red October is a 1990 film based on the 1984 Tom Clancy novel of the same name about the captain of a technologically advanced Soviet ballistic missile submarine that attempts to defect to the United States. James Bond first appeared in 1953. While the primary antagonists in the majority of the novels were Soviet agents, the films were only vaguely based on the Cold War. The Bond movies followed the political climate of the time in their depictions of Soviets and "Red" Chinese.
=== Music === Morgan Freeman's Symphonic Blues Experience released their first album in 2026 with guest appearances by Keb’ Mo’, Shemekia Copeland, Anthony "Big A" Sherrod, the Chineke! Orchestra, Lady Adrena and others. The first single from the album, "Death Letter Blues," featured Grammy-winner Taj Mahal.
== Uses == In Indonesia, Strobilanthes alternata is used to promote urination, check and heal hemorrhages, stop dysentery, and treat venereal diseases. The plant is popular in the United States and rarely the United Kingdom to use in hanging baskets for gardens.The botanical name of Red flame ivy is Hemigraphis colorata Blume.
Menthyl nicotinate is an organic compound with the formula C16H23NO2. It is the ester of nicotinic acid (niacin, vitamin B3) and menthol. At room temperature, menthyl nicotinate is a colorless, odorless, viscous liquid. Being a topical lipophilic niacin derivative, menthyl nicotinate is used in cosmetics and personal care products, personal lubricants and intimate hygiene compositions. Menthyl nicotinate is rapidly absorbed through the stratum corneum and slowly hydrolyzed by skin esterase into niacin and menthol. Such time-dependent release of niacin and menthol, in an equimolar ratio, prevents the excessive niacin-flush effect that is usually observed with other nicotinates. Niacin is a precursor to coenzyme nicotinamide adenine dinucleotide (NAD), which is essential to all cellular processes involved in immune response and DNA-repairing of photodamaged skin cells. Niacin has also been used and tested for the purpose of enhancing detoxification by removing skin lipid-stored xenobiotics. In vitro testing has evidenced menthyl nicotinate's fast skin absorption kinetics and slow percutaneous delivery of niacin. Its antioxidant, antipollution, and protective efficacy against different kinds of damaging agents (UV radiation, oxidizing agents, urban particulates, and cigarette smoke) has also been evaluated. Results indicate that menthyl nicotinate significantly enhances skin barrier function.
== The Strep-tag principle == Just like other short-affinity tags (His-tag, FLAG-tag), the Strep-tag can be easily fused to recombinant proteins during subcloning of its cDNA or gene. For its expression, various vectors for various host organisms (E. coli, yeast, insect, and mammalian cells) are available. A particular benefit of the Strep-tag is its rather small size and the fact that it is biochemically almost inert. Therefore, protein folding or secretion is not influenced and usually it does not interfere with protein function. Strep-tag is especially suited for analysis of functional proteins, because the purification procedure can be kept under physiological conditions. This not only allows the isolation of sensitive proteins in a native state, but it is also possible to purify intact protein complexes, even if just one subunit carries the tag. In the first step of the Strep-tag purification cycle, the cell lysate containing Strep-tag fusion protein is applied to a column with immobilized Strep-Tactin (step 1). After the tagged protein has specifically bound to Strep-Tactin, a short washing step with a physiological buffer (e.g. phosphate buffered saline, PBS) removes all other host proteins (step 2). This is due to Strep-Tactin's low tendency to bind proteins non specifically. Then, the purified Strep-tag fusion protein is gently eluted with a low concentration of desthiobiotin, which specifically competes for the biotin binding pocket (step 3). To regenerate the column, desthiobiotin is removed by application of a HABA containing solution (a yellow azo dye).
Sources: en.wikipedia.org
=== Liquid chromatography EI-MS === Two recent approaches for coupling capillary scale liquid chromatography-electron ionization mass spectrometry (LC-EI-MS) can be incorporated for the analysis of various samples. These are capillary-scale EI-based LC/MS interface and direct-EI interface. In the capillary EI the nebulizer has been optimized for linearity and sensitivity. The direct-EI interface is a miniaturized interface for nano- and micro-HPLC in which the interfacing process takes place in a suitably modified ion source. Higher sensitivity, linearity, and reproducibility can be obtained because the elution from the column is completely transferred into the ion source. Using these two interfaces electron ionization can be successfully incorporated for the analysis of small and medium-sized molecules with various polarities. The most common applications for these interfaces in LC-MS are environmental applications such as gradient separations of the pesticides, carbaryl, propanil, and chlorpropham using a reversed phase, and pharmaceutical applications such as separation of four anti-inflammatory drugs, diphenyldramine, amitriptyline, naproxen, and ibuprofen. Another method to categorize the applications of electron ionization is based on the separation technique which is used in mass spectroscopy. According to this category most of the time applications can be found in time of flight (TOF) or orthogonal TOF mass spectrometry (OA-TOF MS), Fourier transform ion cyclotron resonance (FT-ICR MS) and quadrupole or ion trap mass spectrometry.
It combines peptide-coated iron oxide attached to "reporter chemicals". When a peptide binds to a thrombin molecule, the report is released and appears in the urine where it can be detected. Human testing has not been conducted.
== Function == The trachea's main function is to transport air to and from the lungs. It also helps to warm, humidify, and filter the air before it reaches the lungs. The trachea is made up of rings of cartilage, which help to keep it open and prevent it from collapsing. The inside of the trachea is lined with a mucous membrane, which produces mucus to help trap dirt and dust particles. The cilia, which are tiny hairs that line the mucous membrane, help to move the mucus and trapped particles up and out of the trachea.
The smaller size and single domain make these antibodies easier to transform into bacterial cells for bulk production, making them ideal for research purposes. Single-domain antibodies are being researched for multiple pharmaceutical applications, and have potential for use in the treatment of acute coronary syndrome, cancer, Alzheimer's disease, and COVID-19.
== Use == So far, biomass-based production of industrial microalgae has been widely applied in the fields from food and feed to high-value chemicals for pharmaceutical and ecological applications. Although the commercial cultivation of microalgae became increasingly popular, only algal biomass is processed to current products, while huge volumes of algae-free media are unexploited in flow through cultures and after biomass harvesting of batch cultures. Medium recycling to save culturing costs faces the big risk of growth inhibition. High volumes of spent media give rise to environmental pollution and cost of water and nutrition supply in cultivation when the media are discarded directly to the environment. Therefore the application of recycling methods motivated by the simultaneous generation of high value products from spent medium bears potential in commercial and environmental perspectives.
Sources: en.wikipedia.org
On 23 April, Trump announced that Israel and Lebanon agreed to a three-week extension of the ceasefire. On 15 May, the truce was extended by Israel and Lebanon for another 45 days. On 1 June, Israel and Hezbollah agreed to a ceasefire, with Israel committing not to target Beirut's southern suburbs and Hezbollah vowing not to attack Israel, under a US proposal aiming to extend the ceasefire to all of Lebanon. On 3 June, Israel and Lebanon reached an agreement to renew the ceasefire, facilitated by the US, and to create "pilot zones". On 4 June, Hezbollah rejected the previously announced truce deal, demanding instead a comprehensive truce and a full withdrawal of Israel from Lebanon. On 19 June, President Trump announced that Israel and Hezbollah have reached a truce, facilitated by the US, Qatar, and Iran. On 26 June, US Secretary of State Marco Rubio announced a framework deal between Israel and Lebanon for "lasting peace and security" via US mediation. The agreement includes a cease-fire, requiring Hezbollah to end hostilities and withdraw from southern Lebanon, but it was subsequently rejected by Hezbollah.
Analgesics are frequently used in combination, such as the paracetamol and codeine preparations found in many non-prescription pain relievers. They can also be found in combination with vasoconstrictor drugs such as pseudoephedrine for sinus-related preparations, or with antihistamine drugs for people with allergies. While the use of paracetamol, aspirin, ibuprofen, naproxen, and other NSAIDs concurrently with weak to mid-range opioids (up to about the hydrocodone level) has been said to show beneficial synergistic effects by combating pain at multiple sites of action, several combination analgesic products have been shown to have few efficacy benefits when compared to similar doses of their individual components. Moreover, these combination analgesics can often result in significant adverse events, including accidental overdoses, most often due to confusion that arises from the multiple (and often non-acting) components of these combinations.
Analysis of Sulfolobus solfataricus CRISPRs revealed further complexities to the canonical model of spacer insertion, as one of its six CRISPR loci inserted new spacers randomly throughout its CRISPR array, as opposed to inserting closest to the leader sequence. Multiple CRISPRs contain many spacers to the same phage. The mechanism that causes this phenomenon was discovered in the type I-E system of E. coli. A significant enhancement in spacer acquisition was detected where spacers already target the phage, even mismatches to the protospacer. This 'priming' requires the Cas proteins involved in both acquisition and interference to interact with each other. Newly acquired spacers that result from the priming mechanism are always found on the same strand as the priming spacer. This observation led to the hypothesis that the acquisition machinery slides along the foreign DNA after priming to find a new protospacer.
=== Introduction of consumer-ready hardware (2010s–present) === The popularity of digital gaming across multiple forms like mobile, console, or PC gaming, led technology giants to further invest in the development of VR technology. In a thriving gaming market, the advancement in VR technology has been a point of great interest in the age of modern gaming. One catalyst to this modern VR boom was the obsession and great success of Pokémon Go in 2016, which incorporated basic VR concepts, stirring the world with technological breakthroughs in gaming such as VR effects, combining real life scenes with the virtual world, as well as the concept of enjoying gaming alongside interaction in the real world. After decades of attempts from its introduction, low-cost, consumer-grade VR hardware began to appear in the 2010s. The Oculus Rift is considered the first consumer-ready VR headset and was first released in 2016. The unit was developed by Palmer Luckey, and first announced in 2013 as an inexpensive VR option for video games. During testing, Luckey had gained the help of id Software's John Carmack to develop a VR version of Doom 3 for Oculus. While this helped to successfully demonstrate the Oculus, which led to Facebook acquiring Oculus in 2014 for $2 billion, it also led to a lawsuit between ZeniMax Media, id's parent company, against Oculus over intellectual property theft over Carmack's participation. The case was settled out of court. Nine games were available at launch and Oculus had established a number of partnerships to provide more games following its release.
Rosiglitazone (trade name Avandia) is an antidiabetic drug in the thiazolidinedione class. It works as an insulin sensitizer, by binding to the PPAR in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5 billion in 2006; however, following a meta-analysis in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5 million in 2012. The drug's patent expired in 2012. It was patented in 1987 and approved for medical use in 1999. Despite rosiglitazone's effectiveness at decreasing blood sugar in type 2 diabetes mellitus, its use decreased dramatically as studies showed apparent associations with increased risks of heart attacks and death. Adverse effects alleged to be caused by rosiglitazone were the subject of over 13,000 lawsuits against GSK; as of July 2010, GSK had agreed to settlements on more than 11,500 of these suits. Some reviewers recommended rosiglitazone be taken off the market, but an FDA panel disagreed, and it remains available in the US. From November 2011 until November 2013, the US federal government did not allow Avandia to be sold without a prescription from a certified doctor; moreover, patients were required to be informed of the risks associated with its use, and the drug had to be purchased by mail order through specified pharmacies.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.